A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them

Plus: FDA hold on Entrada’s DMD treatment and updates from Atara, AZ, LianBio-Pfizer, F2G, Protillion, and more 

Ipsen’s choice to partner with Exicure on two neurodegeneration programs comes as the Chicago-based biotech has shown a rising interest in neuroscience, with its R&D day last month

Deal marks Ipsen’s return to Parkinson’s as it seeks to build its neuroscience pipeline

BioCentury’s roundup of preclinical news